Once-weekly semaglutide in adolescents with obesity

Cited by (794)

Items 201–300 of 794

1. The Promise of Adjunct Medications in Improving Type 1 Diabetes Outcomes: Glucagon-Like Peptide Receptor Agonists
   Sujatha Seetharaman, Eda Cengiz · 2024 · Journal of Diabetes Science and Technology
2. Focus on Glucagon-like Peptide-1 Target: Drugs Approved or Designed to Treat Obesity
   Jiahua Zhang, Jintao Wei, Weiwen Lai, Jiawei Sun, Yan Bai, Hua Cao, Jiao Guo, Zhengquan Su · 2025 · International Journal of Molecular Sciences
3. Pharmacological and physiological activation of TGR5 in the NTS lowers food intake by enhancing leptin-STAT3 signaling
   Kyla Bruce, Song‐Yang Zhang, Ameth N. Garrido, Melissa T Wang, Tomás P. Bachor, Pengcheng Wang, Allison Wanting Xu, Zeyu Yang, Tony K.T. Lam · 2025 · Nature Communications
4. 12-month outcomes of GLP - 1 in severe pediatric obesity: real-world data
   Louise Cominato, Mariana L. Resende, Natália Bernardes, Ludmila L. Rachid, Caroline Passone, Larissa Baldini Farjalla Mattar, Georgia Neme, Sonia Fátima Leal de Souza, Claudia Renata Pinto dos Santos, Ruth Rocha Franco et al. · 2025 · Frontiers in Endocrinology
5. Glucagon‐like peptide‐1 receptor agonists in pediatric metabolic dysfunction‐associated steatotic liver disease
   Andrea M. Tou, Jennifer A. Panganiban · 2025 · Journal of Pediatric Gastroenterology and Nutrition
6. The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis
   Christina Dam Bjerregaard Sillassen, Johanne Juul Petersen, Pascal Faltermeier, Delal Yucel, Faiza Siddiqui, Rebecca Kjær Andersen, Leonardo Graever, Jonas Leth Bjerg, Caroline Barkholt Kamp, Johannes Grand et al. · 2025 · BMC Medicine
7. A Systematic Review Identifying Critical Evidence Gaps in Reporting Dietary Change in Randomized Controlled Trials Prescribing Liraglutide, Semaglutide, or Tirzepatide
   Anna K. Jansson, María Gómez‐Martín, Linnea E. Hedin, Erin D. Clarke, Victoria Cross, Jordan Stanford, Rachael Taylor, Leonie Helen Bogl, Nienke de Vlieger, Afsaneh Koochek et al. · 2026 · Obesity Reviews
8. Interplay of childhood metabolic dysfunction-associated steatotic liver disease and obesity in the development of youth-onset type 2 diabetes
   Razieh Parizad, Juniali Hatwal, Ajit Singh Brar, Leila Alizadeh, Manjeet Kumar Goyal, Akash Batta, Bishav Mohan · 2026 · World Journal of Clinical Pediatrics
9. 15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist–induced weight loss
   Minas Nalbandian, Jameel Lone, E. Le Moal, Ireh Kim, Kaitlin Jeuris, Y. Li, Peggy Kraft, Meng Zhao, K. Koleckar, Zeyuan Zhang et al. · 2026 · Proceedings of the National Academy of Sciences of the United States of America
10. European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) steatotic liver disease special interest group position paper on screening, diagnosis and investigation of paediatric metabolic dysfunction‐associated steatotic liver disease
    Jake Peter Mann, Sander Lefere, Maarten Buytaert, Anna Alisi, Cigdem Arikan, Jernej Brecelj, Rachel M. Brown, Irene Degrassi, Giulia Fiore, Emer Fitzpatrick et al. · 2026 · Journal of Pediatric Gastroenterology and Nutrition
11. Metabolic and Bariatric Surgery in Children: Current Practices and Outcomes
    Shayan A. Shah, Noor A. Khan, Faisal Qureshi · 2024 · Current Obesity Reports
12. Glucagon‐like‐peptide 1 receptor agonism and attempted suicide: A Mendelian randomisation study to assess a potential causal association
    Anthony Nguyen, Emily Smith, Habiba Hashemy, Sri Mahavir Agarwal, Margaret Hahn, Andrew D. Paterson, Satya Dash · 2024 · Clinical Obesity
13. Glucagon-Like Peptide 1 Receptor Agonists for Obesity: Efficacy, Side Effects, and Risks
    Sanjana Thota-Kammili, Elif Tama, Maria D. Hurtado Andrade · 2024 · Current Treatment Options in Gastroenterology
14. Cognitive function in adolescence and the risk of early-onset stroke
    Aya Bardugo, Cole D. Bendor, Carmit Libruder, Miri Lutski, Inbar Zucker, Avishai M. Tsur, Estela Derazne, Gal Yaniv, Raquel C. Gardner, Hertzel C. Gerstein et al. · 2024 · Journal of Epidemiology & Community Health
15. Practice Patterns of Glucagon-Like Peptide-1 Agonist Use Among Pediatric Bariatric Surgeons: A National Survey
    Michael A. Kochis, Christa Bizimana, Jeffrey L. Zitsman, Janey S.A. Pratt, Cornelia L. Griggs · 2024 · Journal of Surgical Research
16. Annonaceous acetogenins mimic AA005 targets mitochondrial trifunctional enzyme alpha subunit to treat obesity in male mice
    Bing Han, Zhanming Li, Xu-Yun Zhao, Kai Liang, Yuqin Mao, Shilong Zhang, Liying Huang, Chao‐Yue Kong, Xin Peng, Hui‐Ling Chen et al. · 2024 · Nature Communications
17. Old and new anti-obesity drugs
    Salimeh Dodangeh, Shirin Hasani‐Ranjbar · 2024 · Journal of Diabetes & Metabolic Disorders
18. Youth Perspectives on the Use of Medications for Weight Loss
    Vaishnavi Peyyety, Margaret Jankowski, Sarah Apte, Jasmine Sindelar, Rawan Elrajabi, Tammy Chang, Kendrin R. Sonneville, Mary Ellen Vajravelu · 2025 · Journal of Adolescent Health
19. ESI Clinical Practice Guidelines for the Evaluation and Management of Obesity in India – An Update (2025)
    Sri Venkata Madhu, Nitin Kapoor, Sambit Das, Nishant Raizada, Sanjay Kalra · 2025 · Indian Journal of Endocrinology and Metabolism
20. The prevention of adult cardiovascular disease must begin in childhood: evidence and imperative
    Michael Khoury, Adam L. Ware, Brian W. McCrindle · 2025 · Nature Reviews Cardiology
21. Targeting the Gut Microbiota in Pediatric Obesity: A Paradigm Shift in Prevention and Treatment? A Comprehensive Review
    Gianmario Forcina, Pierluigi Di Filippo, Delia De Biasio, Francesco Giustino Cesaro, Vittoria Frattolillo, Alessia Massa, Maria De Cesare, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa · 2025 · Nutrients
22. Screening, Diagnosis, and Management of Pediatric Hypertriglyceridemia: A Scientific Statement From the American Heart Association
    Amy Lynn Hering Peterson, Ambika P. Ashraf, Jennifer Bachman, Robert Alexander Hegele, Maya Rashad, Andrew Michael South, Andrew H. Tran, Justin P.V. Zachariah, Jonathan P. Wong · 2026 · Arteriosclerosis Thrombosis and Vascular Biology
23. Visceral adipose tissue and risk of diabetic nephropathy: A Mendelian randomization study
    Min Tao, Guanghong Zhou, Jing Liu, Miao He, Xie Luo, Cong Wang, Lili Zhang · 2024 · Diabetes Research and Clinical Practice
24. Efficacy of liraglutide in pediatric obesity: A review of clinical trial data
    Marcello Agosta, Maria Sofia, Salvatore Pezzino, Sara D’Amato, Giorgia Litrico, Chiara Mazzone, Gaetano La Greca, Saverio Latteri · 2024 · Obesity Medicine
25. Clinical effectiveness and predictors of response to topiramate plus lifestyle modification in youth with obesity seen in a weight management clinical setting
    Eric Morris Bomberg, Justin Clark, Kyle D. Rudser, Amy C. Gross, Aaron S. Kelly, Claudia K. Fox · 2024 · Frontiers in Endocrinology
26. Once-Weekly Semaglutide in Adolescents with Obesity
    Daniel Weghuber, Aaron S Kelly, Silva A Arslanian · 2023 · New England Journal of Medicine
27. An open‐label 16‐week study of liraglutide in adolescents with obesity post‐sleeve gastrectomy
    Anna Zenno, Ejike E. Nwosu, Syeda Fatima, Evan P. Nadler, Nazrat M. Mirza, Sheila M. Brady, Sara A. Turner, Shanna B. Yang, Julia Lazareva, Jennifer Te‐Vazquez et al. · 2024 · Pediatric Obesity
28. Mib2 Regulates Lipid Metabolism in Heart Failure With Preserved Ejection Fraction via the Runx2–Hmgcs2 Axis
    Zhulan Cai, Shunyao Xu, Xiaohua Xiao, Chen Liu, Lingyun Zu · 2025 · Journal of Cellular and Molecular Medicine
29. Semaglutide attenuates lipotoxicity-induced cardiac injury by inhibiting Slc27a2 expression
    Xiaoyu Pan, Shuqi Wang, Xiaoman Yang, Boying Jia, Shuchun Chen · 2025 · Chemico-Biological Interactions
30. Real-World Use of Phentermine and Topiramate for Adolescent Obesity: Retrospective Effectiveness and Safety Analysis
    Courtney E. Batt, Olivia C. Puccio, Megan Moriarty Kelsey, Richard E. Boles, Jaime M. Moore · 2025 · Childhood Obesity
31. Updates on Anti-Obesity Medications in Children and Adolescents
    Mostafa Salama, Doha Hassan, Seema Kumar · 2025 · Children
32. Impact of metabolic and bariatric surgery on the paediatric & adolescent metabolome: A systematic review and meta-analysis
    Anuja T. Mitra, Olivia Wing, Bibek Das, Nube Beatriz González Gómez, Haris A Khwaja, Chetan D. Parmar, Matyas Fehervari · 2025 · Scientific Reports
33. Current and Future Pharmacological Interventions for Acquired Hypothalamic Obesity
    Christian Ludwig Roth, Nathalie J. Doelman-Oldenburger, Hanneke Margo van Santen · 2026 · Drugs
34. Vertical Sleeve Gastrectomy Versus Comprehensive Lifestyle Intervention for Adolescents With Metabolic Dysfunction–Associated Steatotic Liver Disease: A Prospective Controlled Cohort Study
    Toshifumi Yodoshi, Nicholas Jay Ollberding, Meghan McNeill, Sanita L. Ley, Shelley Kirk, David E. Kleiner, Ana Catalina Arce‐Clachar, Kristin Bramlage, Thomas H. Inge, Michael A. Helmrath et al. · 2026 · Alimentary Pharmacology & Therapeutics
35. Conditional average treatment effect estimation with marginally constrained models
    Wouter A. C. van Amsterdam, Rajesh Ranganath · 2023 · Journal of Causal Inference
36. O RISCO DE INTOXICAÇÃO PELO USO DO OZEMPIC (SEMAGLUTIDA) EM PACIENTES NÃO DIABÉTICOS
    Rebecka Marques Gomes Sagratzki, Suellen Souza da Silva, Auro Régio Rocha Mascarenhas, Carolline Sabino Póvoa, Eduarda Martins Souza, Jonathan Tavares da Silva, Pedro Henrique Queiroz Dos Santos, Vinicios Batista Monteiro Silva, Maykon Jhuly Martins de Paiva · 2023 · Brazilian Journal of Implantology and Health Sciences
37. Effective and appropriate use of weight loss medication in pediatric obesity: a narrative review
    Lindsey Yoojin Chung · 2024 · Journal of Yeungnam Medical Science
38. Obesity management in the pediatric patient
    Kelly L. Matson, Norman E. Fenn · 2024 · American Journal of Health-System Pharmacy
39. Use of GLP-1 Receptor Agonists for the Management of Type 1 Diabetes: A Pediatric Perspective
    Michal Nevo-Shenker, Shlomit Shalitin · 2024 · Hormone Research in Paediatrics
40. Family meals on prescription as treatment for childhood obesity—a randomized controlled trial
    Terese Torstensson, Anna Bohlin, Gerd Almquist‐Tangen, Josefine Roswall, Jenny M. Kindblom, Lovisa Sjögren · 2024 · European Journal of Pediatrics
41. Integrating Genetic Insights, Technological Advancements, Screening, and Personalized Pharmacological Interventions in Childhood Obesity
    Robert Šket, Barbara Slapnik, Primož Kotnik, Klementina Črepinšek, Barbara Čugalj Kern, Tine Tesovnik, Barbara Jenko Bizjan, Blaž Vrhovšek, Žiga Iztok Remec, Maruša Debeljak et al. · 2024 · Advances in Therapy
42. Insights into the neurobiology of weight loss after bariatric surgery and GLP-1R agonists
    Tyler M. Cook, Kelly N. Z. Fuller, Darleen A. Sandoval · 2024 · Neuropharmacology
43. The promise of incretin-based pharmacotherapies for metabolic dysfunction-associated fatty liver disease
    Harendran Elangovan, Jenny Elizabeth Gunton, Ming‐Hua Zheng, Jian-Gao Fan, George Boon‐Bee Goh, Henning Grønbæk, Jacob George · 2025 · Hepatology International
44. Weight loss following lisdexamfetamine in children and adolescents with attention deficit hyperactivity disorder and overweight and obesity
    Mostafa Salama, Kaitlin N. Leopold, Roland C. Hentz, Seema Kumar · 2025 · Pediatric Obesity
45. Reassessing type 2 diabetes in adolescents and its management strategies based on insulin resistance
    Qian-You Jia, YanMin Zhang, BaoFeng Zhang, Xuedong An · 2024 · Frontiers in Endocrinology
46. Antiobesity Pharmacotherapy for Patients With Genetic Obesity Due to Defects in the Leptin-Melanocortin Pathway
    Mila Sofie Welling, Elisabeth F. C. van Rossum, Erica L T van den Akker · 2025 · Endocrine Reviews
47. GLP-1 Receptor Agonists for Treatment of Pediatric Obesity: Behavioral Health Considerations
    Grace Jhe, Amy Heard Egbert, Carolyn E. Ievers‐Landis, Eileen A. Chaves, Kimberly Genuario, Melissa Santos, Elvin Thomaseo Burton · 2025 · Childhood Obesity
48. GLP ‐1 Agonists for Pediatric Psychopharmacology: Opportunities and Cautions
    Michael Bartkoski, Ethan A. Poweleit, Stephani L. Stancil · 2025 · Clinical and Translational Science
49. Repeated Withdrawal of a GLPR Agonist Induces Hyperleptinemia and Deteriorates Metabolic Health in Obese Aging UM ‐ HET3 Mice
    Nisi Jiang, Jiyuan Yin, Noah Lawrence, Jieyi Meng, Laurence T. Maeyens, Ziying Xu, Xin Li, Mbolle Ekane, Ariana Chaudhary, Pengju Cao et al. · 2025 · Aging Cell
50. The evolving landscape of pediatric obesity and metabolic dysfunction-associated steatotic liver disease
    Resthie Rachmanta Putri · 2025 · Frontiers in Pediatrics
51. Obesity and emerging intervention strategies: Mechanistic insights and novel drug targets
    Xingrong Feng, Sheyu Li, Jing Li, Zhiguang Su · 2025 · Chinese Medical Journal
52. Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX ‐ SEMA 2.4 mg, an Italian real‐world study
    Simone Pampanelli, Stefano Terzoni, Paola Pantanetti, Chiara Di Loreto, Alessio Mazzieri, Giovanni Cangelosi, Sara Alberti, Cristina Badiali, Ilenia Grandone, Sara Migliarelli et al. · 2026 · Diabetes Obesity and Metabolism
53. Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies
    Jędrzej Chrzanowski, Magdalena Walicka, Jacek Burzyński, Małgorzata Zaraś, Arkadiusz Michalak, Wojciech Fendler · 2026 · PLoS Medicine
54. The Concept of Healthy Behaviours in Obesity May Have Unintended Consequences
    Hilary C. Craig, Zoë M. Doran, Carel Wynand le Roux · 2022 · Nutrients
55. The need for a change in medical research thinking. Eco-systemic research frames are better suited to explore patterned disease behaviors
    Joachim Peter Sturmberg, Jennifer H. Martin, Francesco Tramonti, Thomas Kühlein · 2024 · Frontiers in Medicine
56. Effectiveness and predictors of weight loss response to phentermine plus lifestyle modifications among youth in a paediatric weight management clinical setting
    Eric Morris Bomberg, Justin Clark, Kyle D. Rudser, Amy C. Gross, Aaron S. Kelly, Claudia K. Fox · 2024 · Pediatric Obesity
57. Efficacy and safety of semaglutide combined with metformin in treating T2DM with overweight or obesity: a systematic review and meta-analysis
    Juan Li · 2024 · American Journal of Translational Research
58. Harnessing Evolution and Biomimetics to Enhance Planetary Health
    Peter Stenvinkel, Paul G. Shiels, Peter Kotanko, Pieter Evenepoel, Richard J. Johnson · 2024 · Journal of the American Society of Nephrology
59. Should Pharmaceuticals Be Used as Weight Loss Interventions for Adolescents Classified as Obese by BMI?
    Astrid Floegel‐Shetty · 2023 · The AMA Journal of Ethic
60. Low Perception of Obesity as a Pathological Condition Among Italian Cardiologists
    Armando Ferrera, Allegra Battistoni, Oreste Lanza, Chiara Rossi, Giuliano Tocci, Massimo Volpe · 2023 · High Blood Pressure & Cardiovascular Prevention
61. Considerations for the design and conduct of pediatric obesity pharmacotherapy clinical trials: Proceedings of expert roundtable meetings
    Aaron S. Kelly, Melanie Bahlke, Jennifer L. Baker, Carine E. de Beaufort, Ruth M. Belin, Helena Fonseca, Paula M. Hale, Jens‐Christian Holm, Daniel S. Hsia, Ania M. Jastreboff et al. · 2024 · Pediatric Obesity
62. Keeping the weight off
    2023 · Nature Medicine
63. Novel strategies for medical management of obesity: mechanisms, clinical implications, and societal impacts—a report from the 25th Annual Harvard Nutrition Obesity Symposium
    Srivastava, Gitanjali, Campbell, Sophia L, Hill, Conner R, Stanley, Takara L, Lawson, Elizabeth A, Apovian, Caroline M, Almandoz, Jaime P, Leggio, Lorenzo, Lakdawalla, Darius N, Dar, Mohammad et al. · 2025 · The American Journal of Clinical Nutrition
64. Short‐Term Weight Loss Outcomes of 1.0 mg Semaglutide Therapy Initiated 6 Months After Sleeve Gastrectomy
    Min He, Yu Wang, Rong Hua, Chong Cao, Bo Xu, Qiwei Shen, Xiaojian Fu, Yikai Shao, Qiyuan Yao · 2025 · Obesity
65. Precision Prevention, Diagnostics, and Treatment of Obesity: Pipedream or Reality?
    Emily K. Woolf, Hanim E. Diktas, Andres J Acosta, John William Apolzan, Jamy D. Ard, Kristen E. Boyle, Jack A. Gilbert, Peter Todd Katzmarzyk, Paul J. Laurienti, Tim Lobstein et al. · 2025 · Obesity
66. The ethics of Wegovy: promoting autonomy in pediatric care
    Nanette Ryan, Julian Savulescu · 2025 · Medicine Health Care and Philosophy
67. Intersection between Eating Disorders and Obesity in Youth: Implications for Treatment
    Alyssa M. Button, Alicia Persaud, Anna B. Tanner, Katherine N. Balantekin, Marian Tanofsky‐Kraff, Hiba Jebeile, Denise E. Wilfley · 2025 · Current Obesity Reports
68. The impact of nutrition, exercise, and pharmacotherapy on menstrual health in adolescents with overweight and obesity
    Julius Wu, Elka E. Jacobson-Dickman · 2025 · Nutrition
69. Multidisciplinary care of pediatric obesity and its impact on sleep: a review
    Ravali R. Inja, Christopher M. Cielo︎ · 2026 · Frontiers in Sleep
70. GLP-1 Receptor Agonist Prescriptions for Adolescents With Obesity and Associated Disparities
    Chungsoo Kim, Mona Sharifi, Joseph S. Ross, Yong Chen, Hua Xu, Harlan M. Krumholz, Yuan Lu · 2026 · Archives of Pediatrics and Adolescent Medicine
71. Gut microbiota and metabolic disease risk in youth
    Quin Yuhui Xie, Jill K. Hamilton, Jayne S. Danska · 2026 · Cell Reports Medicine
72. Fighting the epidemic of pediatric metabolic dysfunction-associated steatotic liver disease: Role of non-invasive diagnostics and early pharmacological intervention
    Nicholas Beng Hui Ng, Andrew Anjian Sng, James Guoxian Huang · 2026 · World Journal of Hepatology
73. Beyond Glycemic Control: GLP-1RA–Based Therapies and Emerging Targets Beyond the Metabolic Axis
    Wojciech Matuszewski, Katarzyna Wołos-Kłosowicz, Paulina Włodarczyk, Patrycja Waśniewska, Robert Modzelewski, Jan Marek Górny, Michał Szklarz, Mikołaj Madeksza, Judyta Karolina Juranek · 2026 · Journal of Clinical Medicine
74. Overlooked Outcomes in Pediatric Obesity Management—Unintended Consequences
    Angela S. Alberga, Sabrina Sacco, Linda Booij · 2023 · Archives of Pediatrics and Adolescent Medicine
75. Practical guidelines for eating disorder risk mitigation in patients undergoing obesity treatment for the pediatric provider
    Katelyn Gordon, Abigail L. Matthews, Meg H. Zeller, Jessica Lin · 2024 · Current Opinion in Pediatrics
76. Optimising healthcare transition of adolescents and young adults to adult care: a perspective statement of the Italian Society of Obesity
    Anita Morandi, Giuseppina Rosaria Umano, Andrea Vania, Valeria Gugliemi, Giovanna Muscogiuri, Claudio Maffeis, Luca Busetto, Silvio Buscemi, Valentino Cherubini, Rocco Barazzoni et al. · 2024 · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity
77. What should I consider when prescribing semaglutide for children living with obesity?
    Boxel Elizabeth van, DAVID J. LIM, Emma J. Lee, Christine Desmond, Nikki L. Davis · 2024 · Archives of Disease in Childhood Education & Practice
78. Clinician’s Guide for Pediatric Anti-obesity Medications
    Wesley P. Dutton, Nina U. Paddu, Amy S. Braddock, Brooke R. Sweeney · 2024 · Pediatric Clinics of North America
79. Obesity in children: inheritance and treatment – state of art 2024
    Małgorzata Wójcik, Agnieszka Zachurzok · 2024 · Pediatric Endocrinology Diabetes and Metabolism
80. Gastroesophageal Reflux and Gastrointestinal Symptoms After Metabolic and Bariatric Surgery in Adolescents: An 8-year Follow-up Analysis
    John B. Rode, Suhail A. Zeineddin, Jane C. Khoury, Todd M. Jenkins, Stephanie R. Sisley, Anita P. Courcoulas, Justin R. Ryder, Marc P. Michalsky, Thomas H. Inge · 2025 · Journal of Pediatric Surgery
81. Advances of deep Neural Networks (DNNs) in the development of peptide drugs
    Yuzhen Niu, Pingyang Qin, Ping Lin · 2025 · Future Medicinal Chemistry
82. Cardiometabolic risk stratification in pediatric obesity: evaluating the clinical utility of fasting insulin and BMI-SDS
    Rasmus Stenlid, Sami El Amrani, Sara Y. Cerenius, Banu Küçükemre Aydın, Hannes Manell, Katharina Mörwald, Julia Lischka, Julian Gomahr, Thomas Pixner, Iris Ciba et al. · 2025 · Cardiovascular Diabetology
83. Semaglutide in Cardiometabolic Diseases: SELECTing the Target Population
    Francesco Natale, Ettore Luisi, Rosa Franzese, Noemi Mollo, Achille Solimene, Valentina Maria Caso, Andrea Corvino, Paolo Golino, Giovanni Cimmino · 2024 · Journal of Cardiovascular Development and Disease
84. Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review
    Abdullah Al Lawati, Ayman N. Alhabsi, Rhieya Rahul, Maria-Luisa Savino, Hamed Alwahaibi, Srijit Das, Hanan Al Lawati · 2025 · Diseases
85. Adipositas und Typ-2-Diabetes (Update 2023)
    Martin Clodi, Hermann Toplak, Michael Resl, Johanna Maria Brix, Deborah Raphaela Leitner, Jürgen Harreiter, Friedrich Hoppichler, Thomas C. Wascher, Karin Schindler, Bernhard H. Ludvik · 2023 · Wiener klinische Wochenschrift
86. Metabolic syndrome in children and adolescents
    Young Suk Shim, Hae Sang Lee, Jin Soon Hwang · 2024 · Journal of Korean Medical Association
87. Unravelling leptin variants: advancing precision medicine in obesity
    Béatrice Dubern, Karine Clément · 2023 · Nature Reviews Endocrinology
88. Metabolic and Bariatric Surgery for Adolescents
    Ihuoma Eneli, Faith Anne N. Heeren, Rochelle L. Cason-Wilkerson, Keeley Jean Pratt · 2024 · Pediatric Clinics of North America
89. Protocol for a randomised, double-blinded, controlled trial of youth with childhood-onset obesity treated with semaglutide 2.4 mg/week: the RESETTLE trial
    Sarah Byberg, Joachim Holt, Rasmus Michael Sandsdal, Louise Aas Holm, Lærke Bruun Madsen, Bodil Christensen, Simon Birk Kjær Jensen, Torben F. Hansen, Jens‐Christian Holm, Signe S. Torekov · 2024 · BMJ Open
90. Preferences of Individuals With Obesity for Online Medical Consultation in Different Demand Scenarios: Discrete Choice Experiments
    Yaolin Hu, Jian Wang, Jianbo Zhou, Yuanyuan Gu, Stephen Nicholas, Elizabeth Maitland · 2024 · Journal of Medical Internet Research
91. A novel human specific lncRNA MEK6-AS1 regulates adipogenesis and fatty acid biosynthesis by stabilizing MEK6 mRNA
    Di Li, Yunhua Chen, Xingyu Zhu, Yanlei Yang, Hongling Li, Robert Chunhua Zhao · 2025 · Journal of Biomedical Science
92. One anastomosis gastric bypass in children and adolescents: An international expert survey
    Mohammad Kermansaravi, Sonja Chiappetta, Mario Musella, Miguel Angel Carbajo, Radwan Kassir, Jean‐Marc Chevallier, Khaled Gawdat, Kuldeepak Singh Kular, Gerhard Prager, Rudolf Alfred Weiner et al. · 2025 · Clinical Obesity
93. Associations of waist circumference to height ratio and body mass index through childhood and adolescence on blood pressure and risk of young adult hepatic steatosis: a cohort study
    Sumona Mandal, Sam D. Leary, Nicholas John Timpson, Kushala W. M. Abeysekera, Julian P. Hamilton-Shield · 2025 · Archives of Disease in Childhood
94. Quantitative analysis of the efficacy characteristics and influencing factors of weight loss drugs in children and adolescents
    Yexuan Wang, Junchao Chen, Yingchun He, Yinghua Lv, Haoyang Guo, Qingshan Zheng, Lujin Li · 2025 · Diabetes Obesity and Metabolism
95. Endoscopic Sleeve Gastroplasty: a Proposal for a Minimal Invasive Endoscopic Approach to Adolescent Obesity
    Glória Pelizzo, Francesca Destro, Silvana Perretta, Irene Paraboschi, Marco Antonio Zappa, Ugo Maria Pierucci · 2025 · Obesity Surgery
96. Efficacy and safety of GLP-1 receptor agonists in the treatment of obese patients with chronic heart failure: a meta-analysis
    Anna Jia, Ming Yang, Tianhong Wang, Yusi Hua, Huimin Lu · 2025 · Frontiers in Cardiovascular Medicine
97. From genes to care: the expanding therapeutic horizon in rare genetic obesities
    Sarah Chalopin, Emilie Guillon, Pauline Faucher, Béatrice Dubern, Karine Clément, Christine Poitou · 2025 · Obesity and Endocrinology
98. Review of Hyperbaric Oxygen Therapy as an Adjunctive Intervention for Metabolic Disorders
    Renata Karaś, Urszula E. Binduga, Paweł Januszewicz, Konrad A. Szychowski · 2025 · Antioxidants
99. GLP-1 receptor agonists reduce body mass index and total daily insulin dose in youth with type 1 diabetes: a retrospective cohort study
    Frances Gonzalez, Mark W. Reid, Jaquelin Flores Garcia, Jennifer K. Raymond, Lily C. Chao · 2025 · Journal of Pediatric Endocrinology and Metabolism
100. Real-World Use of GLP-1 Receptor Agonist Liraglutide in Adolescents with Obesity: A First Longitudinal Single-Center Analysis from Switzerland
     C. Noordam, Urs Eiholzer, Claudia K. Katschnig, Aikaterini Stasinaki, Ilja Dubinski · 2025 · Children